The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of ...

Adds Catalent response. The CEO of Swiss pharmaceuticals behemoth Roche (OTCQX:RHHBY) said he believes antitrust regulators ...

Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...

Last week, U.S. consumer groups and labour unions petitioned the U.S. Federal Trade Commission to block Novo Holdings, the ...

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...

Tectonic Advisors LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 6.6% during the 3rd ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...

U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, ...